Lead Product(s) : Mirodenafil dihydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MHRA Accepts POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial by AriBio Co., Ltd
Details : AR1001 (mirodenafil dihydrochloride) is an oral PDE5 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of patients with Alzheimer's Disease.
Brand Name : AR1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 25, 2024
Lead Product(s) : Mirodenafil dihydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mirodenafil dihydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AR1001 is an oral PDE5 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of patients with Alzheimer's Disease.
Brand Name : AR1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2023
Lead Product(s) : Mirodenafil dihydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?